Limits...
Expression of cyclooxygenase-2 (COX-2) in tumour and stroma compartments in cervical cancer: clinical implications.

Ferrandina G, Lauriola L, Zannoni GF, Distefano MG, Legge F, Salutari V, Gessi M, Maggiano N, Scambia G, Ranelletti FO - Br. J. Cancer (2002)

Bottom Line: CD3, CD4, CD8, CD25, Mast Cell Tryptase monoclonal antibodies were used to characterise stroma inflammatory cells in nine cervical tumours.An inverse relation was found between cyclooxygenase-2 levels (cyclooxygenase-2 IDV) of tumour vs stroma compartment (r=-0.44, P<0.0001).The percentage of cases showing high tumour/stromal cyclooxygenase-2 IDV ratio was significantly higher in patients who did not respond to treatment (93.3%) with respect to patients with partial (60.5%), and complete (43.7%) response (P= 0.009).

View Article: PubMed Central - PubMed

Affiliation: Department of Obstetrics and Gynecology, Catholic University of the Sacred Heart, Largo F. Vito, I-00168 Rome, Italy.

Show MeSH

Related in: MedlinePlus

Tryptase staining in mast cells. Double labelling subtraction consecutive immunostaining of the same COX-2 positive tumour section by anti-COX-2 and anti-tryptase antibodies showed that the vast majority (>70%) of tryptase positive mast cells also express COX-2, insert). Bar: 50 μm.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2376190&req=5

fig5: Tryptase staining in mast cells. Double labelling subtraction consecutive immunostaining of the same COX-2 positive tumour section by anti-COX-2 and anti-tryptase antibodies showed that the vast majority (>70%) of tryptase positive mast cells also express COX-2, insert). Bar: 50 μm.

Mentions: Double labelling subtraction consecutive immunostaining of the same COX-2 positive tumour section by anti-COX-2 and anti-tryptase antibodies showed that the vast majority (>70%) of tryptase positive mast cells also express COX-2 (Figure 5Figure 5


Expression of cyclooxygenase-2 (COX-2) in tumour and stroma compartments in cervical cancer: clinical implications.

Ferrandina G, Lauriola L, Zannoni GF, Distefano MG, Legge F, Salutari V, Gessi M, Maggiano N, Scambia G, Ranelletti FO - Br. J. Cancer (2002)

Tryptase staining in mast cells. Double labelling subtraction consecutive immunostaining of the same COX-2 positive tumour section by anti-COX-2 and anti-tryptase antibodies showed that the vast majority (>70%) of tryptase positive mast cells also express COX-2, insert). Bar: 50 μm.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2376190&req=5

fig5: Tryptase staining in mast cells. Double labelling subtraction consecutive immunostaining of the same COX-2 positive tumour section by anti-COX-2 and anti-tryptase antibodies showed that the vast majority (>70%) of tryptase positive mast cells also express COX-2, insert). Bar: 50 μm.
Mentions: Double labelling subtraction consecutive immunostaining of the same COX-2 positive tumour section by anti-COX-2 and anti-tryptase antibodies showed that the vast majority (>70%) of tryptase positive mast cells also express COX-2 (Figure 5Figure 5

Bottom Line: CD3, CD4, CD8, CD25, Mast Cell Tryptase monoclonal antibodies were used to characterise stroma inflammatory cells in nine cervical tumours.An inverse relation was found between cyclooxygenase-2 levels (cyclooxygenase-2 IDV) of tumour vs stroma compartment (r=-0.44, P<0.0001).The percentage of cases showing high tumour/stromal cyclooxygenase-2 IDV ratio was significantly higher in patients who did not respond to treatment (93.3%) with respect to patients with partial (60.5%), and complete (43.7%) response (P= 0.009).

View Article: PubMed Central - PubMed

Affiliation: Department of Obstetrics and Gynecology, Catholic University of the Sacred Heart, Largo F. Vito, I-00168 Rome, Italy.

Show MeSH
Related in: MedlinePlus